The parallel observations of PDL1-, CTLA-4-, and CD39/CD73-based tolerance in both fields raise the possibility that overcoming immune suppression and releasing tumor cytotoxicity in cancer, as well as enforcing immune regulation in transplant recipients, is becoming increasingly about controlling the EV content of the tumor and transplant micro-environment. Here, ENTPD1 is linked to neoplasm.